Global Blood Therapeutics, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical products and clinical research.
The company stated in the following article that they conduct pre-clinical trials of their drugs on animals.
“In an animal model of SCD, GBT440 inhibited RBC sickling, prolonged the half-life of RBCs and reduced reticulocyte counts. It also exhibited favorable pharmacokinetic properties in various animal species, suggesting the potential for once-daily oral dosing in SCD patients.” Read the full document
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA. [Source: MarketWatch]
Company Website: http://www.globalbloodtx.com